M Sarwar1, C S Samuel2, R A Bathgate3, D R Stewart4, R J Summers1. 1. Drug Discovery Biology, Monash Institute of Pharmacology, Monash University, Australia. 2. Department of Pharmacology, Monash University, Australia. 3. The Florey Institute of Neuroscience and Mental Health and the Department of Biochemistry and Molecular Biology, University of Melbourne, Australia. 4. Corthera Inc., San Mateo, CA, USA.
Abstract
BACKGROUND AND PURPOSE: In the phase III clinical trial, RELAX-AHF, serelaxin caused rapid and long-lasting haemodynamic changes. However, the cellular mechanisms involved are unclear in humans. EXPERIMENTAL APPROACH: This study examined the effects of serelaxin in co-cultures of human primary endothelial cells (ECs) and smooth muscle cells (SMCs) on cAMP and cGMP signalling. KEY RESULTS: Stimulation of HUVECs or human coronary artery endothelial cells (HCAECs) with serelaxin, concentration-dependently increased cGMP accumulation in co-cultured SMCs to a greater extent than in monocultures of either cell type. This was not observed in human umbilical artery endothelial cells (HUAECs) that do not express the relaxin receptor, RXFP1. Treatment of ECs with l-N(G) -nitro arginine (NOARG; 30 μM, 30 min) inhibited serelaxin-mediated (30 nM) cGMP accumulation in HUVECs, HCAECs and co-cultured SMCs. In HCAECs, but not HUVECs, pre-incubation with indomethacin (30 μM, 30 min) also inhibited cGMP accumulation in SMCs. Pre-incubation of SMCs with the guanylate cyclase inhibitor ODQ (1 μM, 30 min) had no effect on serelaxin-mediated (30 nM) cGMP accumulation in HUVECs and HCAECs but inhibited cGMP accumulation in SMCs. Serelaxin stimulation of HCAECs, but not HUVECs, increased cAMP accumulation concentration-dependently in SMCs. Pre-incubation of HCAECs with indomethacin, but not l-NOARG, abolished cAMP accumulation in co-cultured SMCs, suggesting involvement of prostanoids. CONCLUSIONS AND IMPLICATIONS: In co-cultures, treatment of ECs with serelaxin caused marked cGMP accumulation in SMCs and with HCAEC also cAMP accumulation. Responses involved EC-derived NO and with HCAEC prostanoid production. Thus, serelaxin differentially modulates vascular tone in different vascular beds.
BACKGROUND AND PURPOSE: In the phase III clinical trial, RELAX-AHF, serelaxin caused rapid and long-lasting haemodynamic changes. However, the cellular mechanisms involved are unclear in humans. EXPERIMENTAL APPROACH: This study examined the effects of serelaxin in co-cultures of human primary endothelial cells (ECs) and smooth muscle cells (SMCs) on cAMP and cGMP signalling. KEY RESULTS: Stimulation of HUVECs or human coronary artery endothelial cells (HCAECs) with serelaxin, concentration-dependently increased cGMP accumulation in co-cultured SMCs to a greater extent than in monocultures of either cell type. This was not observed in human umbilical artery endothelial cells (HUAECs) that do not express the relaxin receptor, RXFP1. Treatment of ECs with l-N(G) -nitro arginine (NOARG; 30 μM, 30 min) inhibited serelaxin-mediated (30 nM) cGMP accumulation in HUVECs, HCAECs and co-cultured SMCs. In HCAECs, but not HUVECs, pre-incubation with indomethacin (30 μM, 30 min) also inhibited cGMP accumulation in SMCs. Pre-incubation of SMCs with the guanylate cyclase inhibitor ODQ (1 μM, 30 min) had no effect on serelaxin-mediated (30 nM) cGMP accumulation in HUVECs and HCAECs but inhibited cGMP accumulation in SMCs. Serelaxin stimulation of HCAECs, but not HUVECs, increased cAMP accumulation concentration-dependently in SMCs. Pre-incubation of HCAECs with indomethacin, but not l-NOARG, abolished cAMP accumulation in co-cultured SMCs, suggesting involvement of prostanoids. CONCLUSIONS AND IMPLICATIONS: In co-cultures, treatment of ECs with serelaxin caused marked cGMP accumulation in SMCs and with HCAEC also cAMP accumulation. Responses involved EC-derived NO and with HCAEC prostanoid production. Thus, serelaxin differentially modulates vascular tone in different vascular beds.
Authors: Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry Journal: FASEB J Date: 2013-09-13 Impact factor: 5.191
Authors: Piotr Ponikowski; Veselin Mitrovic; Mikhail Ruda; Alberto Fernandez; Adriaan A Voors; Alexander Vishnevsky; Gad Cotter; Olga Milo; Ute Laessing; Yiming Zhang; Marion Dahlke; Robert Zymlinski; Marco Metra Journal: Eur Heart J Date: 2013-11-18 Impact factor: 29.983
Authors: C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry Journal: Br J Pharmacol Date: 2016-09-30 Impact factor: 8.739
Authors: Anne Steglich; Friederike Kessel; Linda Hickmann; Michael Gerlach; Peter Lachmann; Florian Gembardt; Mathias Lesche; Andreas Dahl; Anna Federlein; Frank Schweda; Christian P M Hugo; Vladimir T Todorov Journal: Pflugers Arch Date: 2019-08-06 Impact factor: 3.657
Authors: Maggie Lam; Simon G Royce; Chantal Donovan; Maria Jelinic; Laura J Parry; Chrishan S Samuel; Jane E Bourke Journal: Front Pharmacol Date: 2016-10-27 Impact factor: 5.810
Authors: Martina Kocan; Mohsin Sarwar; Sheng Y Ang; Jingbo Xiao; Juan J Marugan; Mohammed A Hossain; Chao Wang; Dana S Hutchinson; Chrishan S Samuel; Alexander I Agoulnik; Ross A D Bathgate; Roger J Summers Journal: Sci Rep Date: 2017-06-07 Impact factor: 4.379